At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
Carvedilol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
In Brief
A Phase 2 clinical trial evaluating Carvedilol and placebo for Breast Cancer. Completed, enrolled 82 participants across 2 sites.
Detailed Summary
The purpose of this study is to find out the effects, good and/or bad, of a beta blocker (carvedilol) on heart function during treatment with anti-HER2 medication(s) including trastuzumab (Herceptin).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedJun 2014
Primary CompletionJun 2021
TodayJul 2026
First PostedJun 27, 2014
Enrollment StartJun 24, 2014
Primary CompletionJun 24, 2021
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 12.0 years ago
Interventions
Carvediloldrug
placeboother